Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19894111 | 0.91 | P2RX7 (0.52) | GBA1 | |
| SCHEMBL19893980 | 0.88 | GBA1 (0.60) | GBA1ALDH1A1HTT | |
| SCHEMBL20223578 | 0.88 | L3MBTL1 (0.51) | GBA1KMT2AKDM4E | |
| SCHEMBL19902937 | 0.88 | KDM4E (0.58) | GBA1KMT2AKDM4EHSD17B10HTT | |
| SCHEMBL19893962 | 0.85 | HCRTR1 (0.58) | GBA1KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL19894016 | 0.84 | HCRTR2 (0.59) | GBA1ALDH1A1 | |
| SCHEMBL19894159 | 0.84 | HCRTR1 (0.59) | GBA1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL19894052 | 0.84 | HCRTR1 (0.45) | GBA1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL19894071 | 0.84 | HCRTR1 (0.57) | GBA1HTT | |
| SCHEMBL19894104 | 0.84 | GBA1 (0.61) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287454-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3287454-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| EP-3287454-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-3287454-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155333-A1 | Heterocyclic Compound | HCRTR1, HCRTR2, OXTR | GBA1 1208/4885KMT2A 730/4885RAB9A 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.